Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
Guy Young(Children's Hospital of Los Angeles), Yuqian Shen(Sanofi (United States)), Robert Klamroth(Klinikum im Friedrichshain), Steven W. Pipe(University of Michigan), Savita Rangarajan(Guy's and St Thomas' NHS Foundation Trust), Laurel A. Menapace(National Institutes of Health), Alok Srivastava(M.J.P. Rohilkhand University), Ming‐Ching Shen(National Taiwan University Hospital), Gili Kenet(Sheba Medical Center), Tadashi Matsushita(Nagoya University Hospital), Bülent Zülfikar(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Flora Peyvandi(University of Milan), Chuanwu Zhang(AVEO Oncology (United States)), Kaan Kavaklı(Ege University), Marja Puurunen(Synlogic (United States)), Huyen Tran(The Alfred Hospital), Jing Sun(Qiqihar University), Marek Demissie(Sanofi (United States)), Chur-Woo You(Eulji University)
Cited by 38
Related Papers
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
|British Journal of Haematology|2012|867
Genome sequence and genetic diversity of the common carp, Cyprinus carpio
|Nature Genetics|2014|677
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders
|Journal of Thrombosis and Haemostasis|2012|498
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
|New England Journal of Medicine|2016|494